https://www.proactiveinvestors.com.au Proactiveinvestors RSS feed en Tue, 16 Oct 2018 21:49:43 +1100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Interim Results ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180928070004_13807960/ Fri, 28 Sep 2018 16:00:04 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180928070004_13807960/ <![CDATA[RNS press release - ProAxsis Immunoassays Selected for Large Trial ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180920070017_13797560/ Thu, 20 Sep 2018 16:00:17 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180920070017_13797560/ <![CDATA[RNS press release - Wanda Launches CareLink, New Digital Health App ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180815070001_13755599/ Wed, 15 Aug 2018 16:00:01 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180815070001_13755599/ <![CDATA[RNS press release - ProAxsis Granted Third Respiratory Field CE Mark ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180802070204_13740694/ Thu, 02 Aug 2018 16:02:04 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180802070204_13740694/ <![CDATA[RNS press release - Change of Adviser ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180802070026_13740660/ Thu, 02 Aug 2018 16:00:26 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180802070026_13740660/ <![CDATA[RNS press release - Wanda Technology Enhancements ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180718070005_13721675/ Wed, 18 Jul 2018 16:00:05 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180718070005_13721675/ <![CDATA[News - NetScientific’s Wanda enhances Patient Management Platform with patient adherence features ]]> https://www.proactiveinvestors.com.au/companies/news/201012/netscientifics-wanda-enhances-patient-management-platform-with-patient-adherence-features-201012.html NetScientific PLC (LON:NSCI) has announced that its portfolio company Wanda Technology Enhancements has completed a significant enhancement of its Patient Management Platform to improve patient adherence to care plans.  

The AIM-listed firm said the use of Wanda’s existing platform had been shown to predict 90% of patient-level adverse events up to seven days in advance of their occurrence and allows for virtual intervention to prevent such events.

READ:NetScientific portfolio company Vortex Biosciences appoints new chief executive officer

The healthcare IP commercialisation group said the new enhanced Patient Reminder Suite empowers clinicians to better engage patients in care plan adherence through personalised reminders and alerts. These alerts can be pre-scheduled and delivered via multi-modal communications.

NetScientific said the enhancements also include the adoption of the cloud Text-to-Speech Application Programming Interface from Google that uses machine learning to deliver natural-sounding human voice automation.

Francois R. Martelet, NetScientific's chief executive officer and chairman of Wanda, said: "Wanda's enhancements to its core technology mean that relationships between clinicians and patients will continue to improve, and will empower patients to take a more active role in the management of their diseases as well as increase their quality of life.”

He added: “We continue to see invaluable potential in Wanda and look forward to monitoring its progress in the coming months."

]]>
Wed, 18 Jul 2018 07:33:00 +1000 https://www.proactiveinvestors.com.au/companies/news/201012/netscientifics-wanda-enhances-patient-management-platform-with-patient-adherence-features-201012.html
<![CDATA[RNS press release - Grant of Options to Directors ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180626162418_13694523/ Wed, 27 Jun 2018 01:24:18 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180626162418_13694523/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180621133333_13689019/ Thu, 21 Jun 2018 22:33:33 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180621133333_13689019/ <![CDATA[RNS press release - Bob Englert Appointed CEO of Vortex Biosciences ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180606070012_13668368/ Wed, 06 Jun 2018 16:00:12 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180606070012_13668368/ <![CDATA[News - NetScientific portfolio company Vortex Biosciences appoints new chief executive officer ]]> https://www.proactiveinvestors.com.au/companies/news/198342/netscientific-portfolio-company-vortex-biosciences-appoints-new-chief-executive-officer-198342.html NetScientific PLC (LON:NSCI) has announced that its portfolio company Vortex Biosciences has appointed Bob Englert as new chief executive officer.

The healthcare IP commercialisation group said Bob Englert, who is currently chief technology officer, takes up the position with immediate effect, replacing Gene Walther, who has resigned to pursue other interests.

READ: NetScientific portfolio company ProAxsis receives grant by Invest North Ireland

The company said Bob Englert, who has been chief technology officer of Vortex since 2016, has over 25 years of global experience in medical devices and life sciences, with a particular focus on IVD, Point of Care, digital health solutions.

Vortex has also appointed Steve Crouse, who has been chief commercial officer since March 2016, to the position of chief operating officer. He will work closely with Bob Englert and the board to drive R&D and commercialisation strategies.

François R. Martelet, CEO of NetScientific and chairman of Vortex Biosciences, said: “Vortex is approaching a critical commercialisation phase with its unique CTC isolation technology, and Bob is in a unique position to drive this forward.”

He added: “With expertise gained from his role as chief technology officer and underpinned by years of industry experience, particularly in the diagnostics field, we believe he is the right person to take Vortex through the next phase of its growth.”

]]>
Wed, 06 Jun 2018 08:01:00 +1000 https://www.proactiveinvestors.com.au/companies/news/198342/netscientific-portfolio-company-vortex-biosciences-appoints-new-chief-executive-officer-198342.html
<![CDATA[RNS press release - ProAxsis Wins Innovative Business of Year in NI ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180604070012_13664849/ Mon, 04 Jun 2018 16:00:12 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180604070012_13664849/ <![CDATA[RNS press release - ProAxsis Awarded Invest NI Grant ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180601070007_13662778/ Fri, 01 Jun 2018 16:00:07 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180601070007_13662778/ <![CDATA[News - NetScientific portfolio company ProAxsis receives grant by Invest North Ireland ]]> https://www.proactiveinvestors.com.au/companies/news/198070/netscientific-portfolio-company-proaxsis-receives-grant-by-invest-north-ireland-198070.html NetScientific PLC (LON:NSCI) has announced its portfolio company ProAxsis  has been awarded a grant by Invest North Ireland to support the development of its proprietary ProteaseTag technology to identify and quantify active protease biomarkers.

The healthcare IP commercialisation group said the project will assist in the clinical validation of new therapeutics for deubiquitinases (DUBs) as part of a £150,000 project.

READ: NetScientific says latest data shows “invaluable potential” of portfolio company Wanda’s technology

The company said DUBs are thought to play significant roles in the pathogenesis of several types of cancer as well as neurodegenerative disorders, and as such are of high interest to the pharmaceutical industry.

NetScientific holds 54% of ProAxsis on a fully-diluted basis.

Francois R. Martelet, chief executive officer of NetScientific and chairman of ProAxsis, said: "The expansion of ProteaseTag technology from serine into cysteine proteases represents a strategic cornerstone for ProAxsis and substantially enlarges the addressable market down the line.”

He added: ”We thank Invest NI and congratulate ProAxsis on its continuing momentum towards becoming the leader in assays for active protease biomarker measurement."

]]>
Fri, 01 Jun 2018 07:27:00 +1000 https://www.proactiveinvestors.com.au/companies/news/198070/netscientific-portfolio-company-proaxsis-receives-grant-by-invest-north-ireland-198070.html
<![CDATA[RNS press release - Notice of AGM and Annual Report & Accounts ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180522162109_13650997/ Wed, 23 May 2018 01:21:09 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180522162109_13650997/ <![CDATA[RNS press release - Wanda Announces Significant Data with Partner HRS ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180521070013_13647919/ Mon, 21 May 2018 16:00:13 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180521070013_13647919/ <![CDATA[News - NetScientific says latest data shows “invaluable potential” of portfolio company Wanda’s technology ]]> https://www.proactiveinvestors.com.au/companies/news/197351/netscientific-says-latest-data-shows-invaluable-potential-of-portfolio-company-wandas-technology-197351.html Netscientific PLC (LON:NSCI) boss Francois Martelet has heaped praise on portfolio company Wanda after new data confirmed the benefits of its technology.

Wanda has developed a system which continuously assesses patients in real time and can detect adverse events up to a week before they happen.

READ: NSCI looking for hard exits as portfolio matures

By using that technology, the number of hospital readmissions for congestive heart failure patients – a patient population with a typically high readmission rate – almost halved (46% reduction).

There are currently 576 patients enrolled on the programme, but Martelet, who is also chairman of Wanda, thinks the latest figures provide a “strong rationale” for rolling out the system to more people.

“The data are impressive as patients with congestive heart failure typically have a very high re-admission rate,” said Martelet.

“This demonstrates the invaluable potential Wanda's technology has in streamlining care and improving patient outcomes.”

He added: “We are entering a new digital era of healthcare in which we firmly believe Wanda can play a pivotal role, and we are very pleased to see the collaboration with HRS working so well.”

NetScientific holds a 62% stake in Wanda.

Shares rose 12.6% to 49p at the opening bell on Monday.

--Updates for share price--

]]>
Mon, 21 May 2018 08:07:00 +1000 https://www.proactiveinvestors.com.au/companies/news/197351/netscientific-says-latest-data-shows-invaluable-potential-of-portfolio-company-wandas-technology-197351.html
<![CDATA[RNS press release - ProAxsis to Present New Data at ATS 2018 ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180502070016_13626643/ Wed, 02 May 2018 16:00:16 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180502070016_13626643/ <![CDATA[News - NetScientific portfolio company to present test data to American Thoracic Society ]]> https://www.proactiveinvestors.com.au/companies/news/196227/netscientific-portfolio-company-to-present-test-data-to-american-thoracic-society-196227.html NetScientific PLC (LON:NSCI) said its portfolio company, ProAxsis, will present data on its NEATstik test to the American Thoracic Society (ATS) conference in San Diego.

The AIM-listed company, which commercialises healthcare IPs, said ProAxsis’ data on NEATstix, its novel point of care test for monitoring active neutrophil elastase (NE) in chronic respiratory disease, demonstrated that it can identify patients with elevated active NE concentrations which could be related to bacterial infections which lead to the conditions.

READ: NetScientific says portfolio company, Vortex BioSciences, to present “compelling new data” at AACR

The group added that ProAxsis would present data on a new high sensitivity version of the assay to the ATS conference, to take place between 19-24 May, which it says provides further validation and underscores the emerging importance of neutrophil elastase as a leading indicator of infection and inflammation in patients with cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and bronchiectasis, and an important drug target. 

Francois Martelet, chief executive of NetScientific and chairman of ProAxsis, said: "The data presented at ATS show that NEATstik can play a role in identifying the role played by a bacterial infection in COPD.

He added: “We are very pleased to see continued validation of the role of neutrophil elastase in respiratory diseases, and excited about presenting data at the prestigious ATS Annual Conference.”

In early morning trading Wednesday, NetScientific shares were steady at 47.5p.

]]>
Wed, 02 May 2018 08:37:00 +1000 https://www.proactiveinvestors.com.au/companies/news/196227/netscientific-portfolio-company-to-present-test-data-to-american-thoracic-society-196227.html
<![CDATA[RNS press release - Directors Dealing Notification ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180418170853_13609965/ Thu, 19 Apr 2018 02:08:53 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180418170853_13609965/ <![CDATA[RNS press release - Result of General Meeting ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180416140446_13606095/ Mon, 16 Apr 2018 23:04:46 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180416140446_13606095/ <![CDATA[RNS press release - Vortex to Present 2 Posters at AACR ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180416072507_13604889/ Mon, 16 Apr 2018 16:25:07 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180416072507_13604889/ <![CDATA[News - NetScientific says portfolio company, Vortex BioSciences, to present “compelling new data” at AACR ]]> https://www.proactiveinvestors.com.au/companies/news/195023/netscientific-says-portfolio-company-vortex-biosciences-to-present-compelling-new-data-at-aacr-195023.html Netscientific PLC (LON:NSCI) announced that its US-based portfolio company, Vortex BioSciences, a leading liquid biopsy company, is to present "compelling new data" at the American Association for Cancer Research (AACR) Annual Meeting bring held in Chicago from 14  April to 18 April 2018.

The transatlantic healthcare IP commercialisation group said the studies support the use of Vortex's non-invasive technology in the characterisation of circulating tumour cells (CTCs) for important clinical biomarkers, namely EGFR and PD-L1.

WATCH: Netscientific PLC raises £5mln to speed up portfolio commercialisation

The firm said these biomarkers play a pivotal role in the development and progression of certain cancer in patients with non-small cell lung cancer (NSCLC).

Commenting on the news, Francois Martelet, Vortex BioSciences’ chairman and CEO of NetScientific said: "The studies presented underscore the potential use of Vortex's technology in the diagnosis and treatment of cancer patients.

“It is paramount to understand which patients are likely to exhibit a superior response to targeted therapies in order to determine the best treatment algorithm, as well as to contain healthcare expenditure.

“We firmly believe that Vortex's technology can play an instrumental role in this."

]]>
Mon, 16 Apr 2018 08:15:00 +1000 https://www.proactiveinvestors.com.au/companies/news/195023/netscientific-says-portfolio-company-vortex-biosciences-to-present-compelling-new-data-at-aacr-195023.html
<![CDATA[RNS press release - Result of Placing ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180411113941_13600585/ Wed, 11 Apr 2018 20:39:41 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180411113941_13600585/ <![CDATA[Media files - Netscientific PLC raises £5mln to speed up portfolio commercialisation ]]> https://www.proactiveinvestors.com.au/companies/stocktube/9050/netscientific-plc-raises-5mln-to-speed-up-portfolio-commercialisation-9050.html Wed, 11 Apr 2018 15:46:00 +1000 https://www.proactiveinvestors.com.au/companies/stocktube/9050/netscientific-plc-raises-5mln-to-speed-up-portfolio-commercialisation-9050.html <![CDATA[RNS press release - Posting of Circular ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180403160918_13590138/ Wed, 04 Apr 2018 01:09:18 +1000 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180403160918_13590138/ <![CDATA[News - Netscientific looks for hard exits as portfolio matures ]]> https://www.proactiveinvestors.com.au/companies/news/194059/netscientific-looks-for-hard-exits-as-portfolio-matures-194059.html “We have five shots on goal, three of which will be this year.”

That’s how Netscientific PLC (LON:NCSI) boss Francois Martelet summed up prospects for the year ahead on a recent visit to Proactive.

WATCH: Majority of NetScientific portfolio now at early commercial stage

By shots on goal, of course, Martelet is referring to the possibility of any one of the five core NetScientific portfolio companies achieving a commercial exit either through a sale or listing, be it totally or partially.

To be at this point for a small biotech IP specialist such as Netscientific is impressive, believes Martelet, but he admits the icing on the cake will be if one of its five core companies moves to the next level.

Newsflow is likely to remain strong as the portfolio companies gear up towards some form of M&A and Martelet is looking for one ‘hard exit’ to give it the flexibility to refresh the portfolio.

READ: Woodford backs fund raise by IP group Netscientific

The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p.

Long-term backer Woodford Investment Management has again showed its support by putting up at least half of the money.

In the document alongside the placing, Netsceintific said Series A financings are planned for Glycotest in this half year and for Vortex and Wanda in late 2018.

The core portfolio Vortex

LIquid biopsy system developer Vortex has already been busy this year.

Vortex’s system collects circulating tumour cells (CTC) from the bloodstream to provide early signs of the killer disease.

Earlier this month, Vortex signed a collaboration deal with BioView, a provider of automated cell imaging and analysis solutions.

Martelet, Vortex’s chairman, said adding BioView to the mix will allow automated identification of the biomarkers expressed by CTCs collected by the platform.

PDS  Biotechnology

PDS Biotechnology, meanwhile, is collaborating on a phase II immuno-therapy trial of its Versamune-based PDS0101 candidate metastatic head and neck cancer in combination with Merck’s best-selling cancer treatment Keytruda.

PDS0101 combines Versamune with harmless multi-epitope peptides derived from cancer-causing proteins of the HPV virus, but, critically, which are recognised by the immune system. 

ProAxsis

ProAxsis is a diagnostics company based in Northern Ireland, developing a range of products to identify active protease biomarkers of diseases.

The tests deploy smart molecules to trap an active protease within a complex biological sample and enable a visual readout of its presence.

Martelet says the business should break-even this year on £1mln of revenues and has just recorded the first sales of its NEATstik point-of-care test for measuring neutrophil elastase, a presence of which is a now being considered as a contributor to lung disease.

Glycotest

Glycotest is developing a test for liver cancers and fibrosis-cirrhosis.

In January, a blind evaluation of 149 patients with hepatocellular carcinoma (HCC), the Panel was able to determine whether or not a patient had liver cancer with a “high predictability”.

“Given that liver cancer is the fastest growing cause of death in the US and the leading cause of death in China, we believe that the positive outcome of the trial will be very significant for patients suffering with HCC.

“Commercially, we believe the opportunity to be very attractive, with an estimated total accessible market of US$1bn annually.”

A series A’ round of funding is likely this year to raise US$10mln.

Wanda

Wanda, based in San Francisco, has developed a way remotely to monitor people with congestive heart failure and other chronic conditions.

Healthcare group HRS is running a pilot of the Wanda product across all of their patients after a successful trial with high-risk heart patients.

At 50.6p, Netscientific is valued at £37mln.

 

]]>
Sun, 01 Apr 2018 09:00:00 +1000 https://www.proactiveinvestors.com.au/companies/news/194059/netscientific-looks-for-hard-exits-as-portfolio-matures-194059.html
<![CDATA[RNS press release - Proposed Placing and Subscription ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180329070010_13585994/ Thu, 29 Mar 2018 17:00:10 +1100 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180329070010_13585994/ <![CDATA[RNS press release - Full Year Results ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180329070008_13585963/ Thu, 29 Mar 2018 17:00:08 +1100 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180329070008_13585963/ <![CDATA[News - Woodford backs fund raise by IP group Netscientific ]]> https://www.proactiveinvestors.com.au/companies/news/194015/woodford-backs-fund-raise-by-ip-group-netscientific-194015.html Woodford Investment Management has put up half of a £5mln fundraising by intellectual property group NetScientific PLC (LON:NSCI).

A placing at 52.5p will raise £5mln, with the possibility of a further £1mln depending on demand.

Woodford has subscribed for 5.7mln new shares. The fund manager already owns 45% of the IP group and as the new shares will take its stake higher, a whitewash waiver is being applied.

READ: Purplebricks boosts Neil Woodford's Patient Capital Trust shares in first half

Netscientific has a core portfolio of five companies and will use the additional funding to accelerate either the float or sale of one or more of these.

Francois Martelet, chief executive, said: “In recent months several of our portfolio companies have reached the commercialisation stage, and we are hoping to move the remaining ones in our portfolio towards commercialisation in the next 18-24 months.

"The additional finance we have raised today will allow us to continue to advance development of investment into our portfolio of companies to provide support at this critical time.

“We are expecting further consolidation in the IP sector and expect to be a significant player in this process.”

Results for 2017 showed an after-tax loss of £9.4mln, with cash of £6.9mln. after a spend of £10.7mln (£12.9mln) over the year.

Martelet added the company does not propose to invest in new opportunities until at least some of its portfolio companies have completed their next external fundraising rounds.

Series A financings are planned for Glycotest in this half year and for Vortex and Wanda in late 2018.

 

]]>
Thu, 29 Mar 2018 08:25:00 +1100 https://www.proactiveinvestors.com.au/companies/news/194015/woodford-backs-fund-raise-by-ip-group-netscientific-194015.html
<![CDATA[RNS press release - Wanda Expanding to Orthopedic Analytics ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180319070007_13571101/ Mon, 19 Mar 2018 18:00:07 +1100 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180319070007_13571101/ <![CDATA[News - NetScientific portfolio company expands into orthopaedics with new partnership ]]> https://www.proactiveinvestors.com.au/companies/news/193360/netscientific-portfolio-company-expands-into-orthopaedics-with-new-partnership-193360.html NetScientific PLC (LON:NSCI) has said its portfolio company, Wanda Health, is expanding into orthopaedics through a new partnership with HRS Home Health (HRS).

The AIM-listed healthcare IP commercialisation group said the partnership would bring Wanda’s specialities in predictive analytics and artificial intelligence (AI) to bear on orthopaedics.

READ: NetScientific says portfolio company Vortex signs partnership deal with cell imaging firm BioView

The company added that initial pilot studies had demonstrated a decrease in the length of time patients were required to remain in hospital through the use of Wanda’s technology by HRS.

NetScientific also said that through the new partnership with HRS, Wanda’s Telehealth and Predictive Analytics would provide real-time data and informatics to orthopaedic surgeons and their clinical teams.

The company added that initial pilot results had demonstrated an 18% decrease in cost per case compared to cases not in the pilot. Length of stay for pilot cases also decreased to 11.5 days from 19.4 days while patients achieved desired outcomes 41% quicker than prior to the pilot.

NetScientific’s chief executive and chairman of Wanda, Francois R. Martelet, said: "We are delighted to announce that Wanda is expanding its analytical focus to orthopaedics, which demonstrates the flexibility and potential of the technology. In particular, we are pleased that the initial pilot cases demonstrate a decrease in length of stay (LOS) from 19.4 days to 11.5 days, achieving desired outcomes for patients 41% quicker when using Wanda technology."

NetScientific currently holds a 61.8% stake on a fully diluted basis in Wanda.

]]>
Mon, 19 Mar 2018 07:50:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193360/netscientific-portfolio-company-expands-into-orthopaedics-with-new-partnership-193360.html
<![CDATA[RNS press release - Vortex Announces Partnership with BioView ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180313070008_13564184/ Tue, 13 Mar 2018 18:00:08 +1100 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180313070008_13564184/ <![CDATA[News - NetScientific says portfolio company Vortex signs partnership deal with cell imaging firm BioView ]]> https://www.proactiveinvestors.com.au/companies/news/193042/netscientific-says-portfolio-company-vortex-signs-partnership-deal-with-cell-imaging-firm-bioview-193042.html NetScientific PLC (LON:NSCI) revealed that its portfolio company Vortex BioSciences has signed a collaboration deal with BioView Ltd, a provider of automated cell imaging and analysis solutions with the aim of providing clinicians with deeper insights into cancer biology.

The AIM-listed transatlantic biomedical and healthcare IP commercialisation group said the partnership will enable Vortex and Bioview to create integrated workflows that will allow the collection of intact circulating tumour cells (CTCs) from blood samples to become part of the standard of care, with a view to increasing the prominence of CTCs in the clinical space as a diagnostic and monitoring tool.

READ: NetScientific announces first sale of point-of-care test from portfolio company

BioView is a publicly traded company on the Tel Aviv Stock exchange, and currently has strategic collaborations underway with international scientific leaders and institutions.

Francois Martelet, NetScientific's CEO and chairman of Vortex, said: “This partnership with BioView will allow automated identification of biomarkers expressed by CTCs collected by Vortex’s platform.”

He concluded: “This technology has potential applications in the fast-evolving field of immuno-oncology and the collaboration represents a critical step for Vortex as it moves towards the clinical market.”

]]>
Tue, 13 Mar 2018 07:36:00 +1100 https://www.proactiveinvestors.com.au/companies/news/193042/netscientific-says-portfolio-company-vortex-signs-partnership-deal-with-cell-imaging-firm-bioview-193042.html
<![CDATA[Media files - Majority of NetScientific portfolio now at early commercial stage ]]> https://www.proactiveinvestors.com.au/companies/stocktube/8866/majority-of-netscientific-portfolio-now-at-early-commercial-stage-8866.html Mon, 12 Mar 2018 13:05:00 +1100 https://www.proactiveinvestors.com.au/companies/stocktube/8866/majority-of-netscientific-portfolio-now-at-early-commercial-stage-8866.html <![CDATA[RNS press release - ProAxsis Reports First NEATstik Sale ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180215070006_13533810/ Thu, 15 Feb 2018 18:00:06 +1100 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180215070006_13533810/ <![CDATA[News - NetScientific announces first sale of point-of-care test from portfolio company ]]> https://www.proactiveinvestors.com.au/companies/news/191688/netscientific-announces-first-sale-of-point-of-care-test-from-portfolio-company-191688.html NetScientific PLC (LON:NSCI), the transatlantic healthcare IP commercialisation group, said today that its portfolio company, ProAxsis, had conducted its first sale of NEATstik®, the company’s point-of-care test for measuring neutrophil elastase.

The NEATstik® test, registered with a CE mark in the second half of 2017, was sold to a research laboratory conducting a respiratory clinical trial for a pharmaceutical company.

READ: NetScientific highlights promising report on portfolio company Vortex BioSciences' cancer technology

The test utilises the company’s proprietary ProteaseTag® technology to allow the rapid, qualitative measurement of the active form of neutrophil elastase, an established biomarker of lung infection and inflammation.

Francois Martelet, Netscientific's chief executive officer and chairman of ProAxsis, said: "We are very pleased to note the first sale of the NEATstik®, which represents a significant milestone for ProAxsis as it begins to commercialise.

"We are also very pleased with the sales performance of the Neutrophil Elastase Immunoassay (NEIA) product, targeted at the research market, where we believe ProAxsis maintains a competitive advantage through its ProteaseTag® technology. We continue to expect ProAxsis will be able to generate over £1mln in revenue for 2018."

WATCH: Majority of NetScientific portfolio now at early commercial stage

NetScientific holds a 57% stake on a fully diluted basis in ProAxsis.

ProAxsis is developing a range of products for the capture, detection, and measurement of active protease biomarkers of diseases.

]]>
Thu, 15 Feb 2018 07:30:00 +1100 https://www.proactiveinvestors.com.au/companies/news/191688/netscientific-announces-first-sale-of-point-of-care-test-from-portfolio-company-191688.html
<![CDATA[RNS press release - Vortex Releases Publication in Nature Scientific ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180209070004_13527329/ Fri, 09 Feb 2018 18:00:04 +1100 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180209070004_13527329/ <![CDATA[News - NetScientific highlights promising report on portfolio company Vortex BioSciences' cancer technology ]]> https://www.proactiveinvestors.com.au/companies/news/191433/netscientific-highlights-promising-report-on-portfolio-company-vortex-biosciences-cancer-technology-191433.html NetScientific PLC (LON:NSCI) has noted that its portfolio company, Vortex BioSciences Inc, has announced a promising report published by Nature Scientific Reports.

The AIM-listed transatlantic healthcare IP commercialisation group said the peer reviewed report, titled "Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer" describes the use of Vortex's technology.

READ: NetScientific hails progress of its portfolio companies in 2017

It added that the technology was used to capture circulating tumour cells (CTCs), in combination with the use of a novel immunofluorescence assay, for measuring programmed cell death ligand 1 (PD-L1) expression on the surface of the CTCs from patients with metastatic non-small cell lung cancer (NSCLC).

Commenting on the news, Francois Martelet, CEO of NetScientific and chairman of Vortex BioSciences said: "This report demonstrates the potential clinical utility of circulating tumour cells captured by the Vortex technology in the treatment of lung cancer patients.

"Recent clinical trials of PD-1 and PD-L1 inhibitors have returned promising clinical responses, providing a rationale for use of the VTX 1 system in personalised medicine."

]]>
Fri, 09 Feb 2018 08:12:00 +1100 https://www.proactiveinvestors.com.au/companies/news/191433/netscientific-highlights-promising-report-on-portfolio-company-vortex-biosciences-cancer-technology-191433.html
<![CDATA[RNS press release - NetScientific Portfolio Update ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180116070004_13497334/ Tue, 16 Jan 2018 18:00:04 +1100 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180116070004_13497334/ <![CDATA[News - NetScientific hails progress of its portfolio companies in 2017 ]]> https://www.proactiveinvestors.com.au/companies/news/190084/netscientific-hails-progress-of-its-portfolio-companies-in-2017-190084.html NetScientific PLC (LON:NSCI), the healthcare intellectual property commercialisation group, said all of its portfolio companies advanced their commercial operations in 2018.

The company gave a quick run-down on milestones achieved by its portfolio companies in 2018 and said the group would continue the commercial and corporate development of all of its portfolio assets to maximise value.

READ:  An overview of NetScientific’s portfolio companies

Glycotest, a US-based liver diagnostics company, has begun planning for a further clinical validation study and to move into the commercial phase, aiming to make its first sale.

It plans to sign a service agreement with a Clinical Laboratory Improvement Amendments-approved lab with the goal of commercialising its HCC Panel test as a clinical lab testing service in the USA.

Cancer diagnostics company Vortex Biosciences is focused on clinical assay development and beginning clinical research studies using existing assays optimised for use with circulating tumour cells, targeting lung cancer diagnostics.

Vortex expects to make these assays available for use with the output of the VTX-1 liquid biopsy system during 2018.

Biomarkers specialist ProAxsis is targeting £1mln in revenue in 2018, with the potential to become free cash flow positive.

The revenue generating projects will be reviewed in the second half of the year to determine ProAxsis's financing requirements.

READ: NetScientific’s portfolio company Glycotest unveils positive data from clinical evaluation of its liver cancer test

Meanwhile, digital health company Wanda aims to initiate a number of new pilot studies to build relationships with new partners, targeting Accountable Care Organisations, Managed Care Organisations and Health Systems as well as Home Healths working with hospital systems.

NetScientific expects new data from these pilots will increase the analytical ability of Wanda's machine learning algorithms to predict hospital readmissions.

A financing event for Wanda in the second half of 2018 remains on the cards, as does another of the group’s portfolio companies, PDS.

"We are pleased to note that all of our core portfolio companies continue to advance their commercial operations and are well positioned for continued momentum as we move into 2018. We are encouraged by the first commercial sales of Vortex's VTX-1 Liquid Biopsy System and the continued expansion of ProAxsis' assay portfolio,” said Francois Martelet, the chief executive officer of NetScientific.

"We look forward to continuing this progress with further developments anticipated early in 2018, including the completion of a Series A fundraising for Glycotest following the company's recent successful clinical trial results for its HCC panel for the diagnosis of liver cancer."

]]>
Tue, 16 Jan 2018 08:29:00 +1100 https://www.proactiveinvestors.com.au/companies/news/190084/netscientific-hails-progress-of-its-portfolio-companies-in-2017-190084.html
<![CDATA[RNS press release - ProAxsis Achieves CE Mark for Plasmin Immunoassay ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180108070005_13487715/ Mon, 08 Jan 2018 18:00:05 +1100 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180108070005_13487715/ <![CDATA[News - NetScientific edges higher after portfolio company ProAxsis granted CE mark for its ProteaseTag ]]> https://www.proactiveinvestors.com.au/companies/news/189642/netscientific-edges-higher-after-portfolio-company-proaxsis-granted-ce-mark-for-its-proteasetag-189642.html Shares in Netscientific PLC (LON:NSCI) bumped higher on Monday morning after its ProAxsis portfolio company received EU approval for its ProteaseTag Active Plasmin Immunoassay.

The award of the CE mark means the product conforms with various EU health, safety and environmental standards and is safe for sale within Europe.

READ: NetScientific’s portfolio company Glycotest unveils positive data from clinical evaluation of its liver cancer test

ProteaseTag is the first CE-marked test which measures the active form of plasmin – a target protease widely believed to be involved in the development of lung disorders such as idiopathic pulmonary fibrosis and acute respiratory distress syndrome.

“We are pleased to announce that ProAxsis has registered a third product with a CE Mark, as it continues to commercialise its growing portfolio of novel protease-targeting point-of-care tests,” said NetScientific chief executive Francois Martelet.

“We are also particularly pleased to announce the first product launch with applications in both respiratory health and other disease states including pre-eclampsia, nephrotic syndrome and diabetes mellitus.”

READ: NetScientific gaining critical mass with commercial ramp-up of portfolio

NetScientific holds a 57% stake in ProAxsis.

Shares in the healthcare IP commercialisation group rose 3.5% to 73.5p early on Monday morning.

]]>
Mon, 08 Jan 2018 08:37:00 +1100 https://www.proactiveinvestors.com.au/companies/news/189642/netscientific-edges-higher-after-portfolio-company-proaxsis-granted-ce-mark-for-its-proteasetag-189642.html
<![CDATA[RNS press release - GlycotestT Completes Diagnostic Evaluation ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180104070002_13484604/ Thu, 04 Jan 2018 18:00:02 +1100 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20180104070002_13484604/ <![CDATA[News - NetScientific’s portfolio company Glycotest unveils positive data from clinical evaluation of its liver cancer test ]]> https://www.proactiveinvestors.com.au/companies/news/189504/netscientifics-portfolio-company-glycotest-unveils-positive-data-from-clinical-evaluation-of-its-liver-cancer-test-189504.html Glycotest, the majority-owned portfolio company of Netscientific PLC (LON:NSCI), has reported positive results from a clinical evaluation of its HCC Panel liver cancer test.

In a blind evaluation of 149 patients with hepatocellular carcinoma (HCC) – the most common form of liver cancer – and control samples, the HCC Panel was able to determine whether or not a patient had liver cancer with a “high predictability”.

WATCH: NetScientific gaining critical mass with commercial ramp-up of portfolio

For those who like the cold, hard figures, the diagnostic panel achieved an AUROC of 0.97 and exhibited 93% sensitivity and 92% specificity – all of which indicates that it’s pretty good at detecting liver cancer.

More effective than current tests

The results back up what Glycotest has found in two previous studies of the HCC Panel: that the diagnostic has the potential to outperform the current dominant blood test.

One of the fundamental issues with current liver cancer tests – generally an alpha-fetoprotein blood test (AFP)– is that they can often miss the tumour.

In a cohort of HCC patients whose tumours had gone undetected by those blood tests, the HCC Panel was able to identify 86% of patients with liver cancer.

In an early-stage cohort of patients with HCC, the HCC Panel was able to identify 78% of patients with liver cancer undetected by AFP blood tests.

US$1bn market

“We are delighted to announce the success of the Chinese clinical trial, which validates the previous clinical studies performed with a combined total of 335 patients,” said NetScientific chief executive Francois Martelet.

READ: NetScientific says portfolio company Wanda granted two new US patents significantly extending protection for core technology

“Given that liver cancer is the fastest growing cause of death in the US and the leading cause of death in China, we believe that the positive outcome of the trial will be very significant for patients suffering with HCC.

“Commercially, we believe the opportunity to be very attractive, with an estimated total accessible market of US$1bn annually.”

NetScientific, which holds an 87.5% stake in Glycotest, saw its shares open 5.1% higher at 72p on Thursday.

]]>
Thu, 04 Jan 2018 08:07:00 +1100 https://www.proactiveinvestors.com.au/companies/news/189504/netscientifics-portfolio-company-glycotest-unveils-positive-data-from-clinical-evaluation-of-its-liver-cancer-test-189504.html
<![CDATA[Media files - NetScientific gaining critical mass with commercial ramp-up of portfolio ]]> https://www.proactiveinvestors.com.au/companies/stocktube/8541/netscientific-gaining-critical-mass-with-commercial-ramp-up-of-portfolio-8541.html Thu, 14 Dec 2017 15:21:00 +1100 https://www.proactiveinvestors.com.au/companies/stocktube/8541/netscientific-gaining-critical-mass-with-commercial-ramp-up-of-portfolio-8541.html <![CDATA[RNS press release - Wanda Awarded Two Patents ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20171212070006_13461627/ Tue, 12 Dec 2017 18:00:06 +1100 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20171212070006_13461627/ <![CDATA[News - NetScientific says portfolio company Wanda granted two new US patents significantly extending protection for core technology ]]> https://www.proactiveinvestors.com.au/companies/news/188631/netscientific-says-portfolio-company-wanda-granted-two-new-us-patents-significantly-extending-protection-for-core-technology-188631.html NetScientific PLC (LON:NSCI) has announced the issue by the US Patent and Trademark Office of two new patents exclusively licensed to its portfolio company, Wanda.

The transatlantic healthcare IP commercialisation group said the patents will significantly extend protection for the core technology used in Wanda's software application for remote health and patient management.

READ: Netscientific associate Vortex Biosciences makes first commercial sale

It added that the patents - titled, "Apparatus, System, and Method for Detecting Activities and Anomalies in Time Series Data" and "Efficient Searching of Stationary Datasets" - are the result of research on clinical time-series data at UCLA.

Commenting on the news, Francois R. Martelet, NetScientific's chief executive officer and Wanda’s chairman said: "We are delighted to announce that Wanda is further strengthening its IP, an important step in its continued corporate development.

READ: NetScientific’s Glycotest subsidiary allowed Chinese patent for liver cancer blood test

“We believe Wanda's class-leading predictive and behavioural analytics platform acts as a competitive differentiator in the emerging and highly exciting Digital Health sector."

]]>
Tue, 12 Dec 2017 07:36:00 +1100 https://www.proactiveinvestors.com.au/companies/news/188631/netscientific-says-portfolio-company-wanda-granted-two-new-us-patents-significantly-extending-protection-for-core-technology-188631.html
<![CDATA[RNS press release - ProAxsis: Sales Update ]]> https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20171121070009_13438235/ Tue, 21 Nov 2017 18:00:09 +1100 https://www.proactiveinvestors.com.au/companies/rns/3656/LSE20171121070009_13438235/ <![CDATA[News - NetScientific portfolio company ProAxsis sees direct sales of ProteaseTag® Active increasing by a factor of three in the second half ]]> https://www.proactiveinvestors.com.au/companies/news/187559/netscientific-portfolio-company-proaxsis-sees-direct-sales-of-proteasetag-active-increasing-by-a-factor-of-three-in-the-second-half-187559.html NetScientific PLC (LON:NSCI) has announced that its portfolio company, ProAxsis has revealed that direct sales of its ProteaseTag® Active Neutrophil Elastase Immunoassay (NEIA) will increase by a factor of three in the second half of 2017 compared to the first half.

The AIM-listed transatlantic healthcare IP commercialisation group added that ProAxsis also expects total revenue to surpass £1mln in 2018.

READ: Netscientific associate Vortex Biosciences makes first commercial sale

Commenting on the news, Francois Martelet, chief executive officer of NetScientific and chairman of ProAxsis, said: "We are pleased to see signs of rapid market adoption of the CE marked NEIA test which uses ProAxsis' market leading ProteaseTag® technology.

“We are especially encouraged to see the acceleration of sales through a combination of repeat orders and new customers from leading research institutions across Europe and the US.”

READ: NetScientific’s Glycotest subsidiary allowed Chinese patent for liver cancer blood test

He added: “We expect 2018 to be a pivotal year for ProAxsis with further planned product launches and potential industry partnerships as value inflection points."

NetScientific holds a 57% stake in ProAxsis on a fully diluted basis.

]]>
Tue, 21 Nov 2017 07:45:00 +1100 https://www.proactiveinvestors.com.au/companies/news/187559/netscientific-portfolio-company-proaxsis-sees-direct-sales-of-proteasetag-active-increasing-by-a-factor-of-three-in-the-second-half-187559.html